RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaJune 20, 2023 - Astrazeneca is considering a corporate restructuring that could help it sidestep the tense confrontation between the US and China countries that has developed in the last few years, and with the United States passage of the IRA, by spinning its Chinese assets into a separately listed company in either Hong Kong or Shanghai.
https://endpts.com/astrazeneca-ponders-a-china-pharma-spinoff-to-protect-itself-from-geopolitical-fallout-ft/